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claim date was designated as the index date. Continuous health plan enrollment 
12 months pre- and post-index date was required. Patients were assigned to four 
monotherapy AED cohorts based on drug class: sodium channel blockers (SCs), 
gamma-aminobutyric acid analogs (GABAs), synaptic vesicle protein 2A binding 
(SV2) and multiple mechanisms (MMs). Adherence was assessed using the propor-
tion of days covered (PDC) and persistence was defined as days to discontinua-
tion with an allowable treatment gap of 45 days without the index AED. Logistic 
and Cox proportional hazards models were used to compare the results among 
the cohorts. RESULTS: Patients in the SC cohort had significantly lower baseline 
Charlson Comorbidity Index scores (1.82), indicating that they were healthier than 
those in the GAMA (2.08, p< 0.001) and SV2 (2.46, p< 0.001) cohorts. Patients in the SC 
cohort were significantly less likely to have a baseline psychiatric disorder (37.6%) 
than those in the GABA (63.8%, p< 0.001) and MM (52.1%, p< 0.001) cohorts. Patients 
treated with GABAs (OR= 0.44, p< 0.001) and MMs (OR= 0.63, p< 0.001) were signifi-
cantly less likely to adhere to their medications (PDC < 80%) than those treated 
with SC. Furthermore, patients treated with GABAs (hazard ratio [HR]= 1.74; 95% 
confidence interval [CI]= 1.59-1.90) and MMs (HR= 1.18; 95% CI= 1.07-1.29) were more 
likely to discontinue treatment during the follow-up period compared to those in the 
SC cohort. CONCLUSIONS: Patients treated with Sodium channel blockers are more 
likely adhere to treatment and have lower discontinuation of AED monotherapy 
than those treated with GABAs and MMs.
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OBJECTIVES: This study examined the relationship between medication adherence 
and outcomes in multiple sclerosis (MS), where both concepts are more difficult to 
measure than in diseases like hypertension where most medications are taken orally 
and surrogate outcomes (e.g., blood pressure) are routinely collected. METHODS: 
MS patients age ≥ 18 years treated at Geisinger Clinic and taking an MS medication 
were surveyed three times, six months apart, to assess medication adherence and 
MS outcomes. Patients reported their doses taken in the past month (adherence), 
number of relapses, TQSM medication satisfaction score, and MSIS physical and 
psychological functional scores. Nonparametric bootstrap analyses were used to 
compare mean outcome scores among patients with and without missed doses. A 
sub-analysis on patients with Geisinger insurance claims was conducted to calcu-
late patient’s MS medication possession ratio (MPR) from 2004 to 2013 and compare 
this claim-based adherence measure with the other results. RESULTS: 306 patients 
completed 971 surveys. Most patients were white (99%), female (85%), ages 22 to 76 
years old (median 50 years). Median time since initial MS diagnosis was 11 years. 
Mean self-reported adherence was 90% (median= 100%, IQR= 92-100%). Most patients 
(80%) reported zero relapses. Patients with no missed doses had significantly higher 
medication satisfaction than those with missed doses (77.5 vs. 72.5, p= 0.0006) and 
better psychological function (32.7 vs. 37.7, p= 0.017). There were no significant dif-
ferences between groups in reported number of relapses or physical functional 
status. MPR could only be calculated for 95 patients (37 had claims but not enough 
to calculate MPR), was extremely high in this subgroup (mean 96%, median 98%) 
and did not show the same associations with patient outcomes. CONCLUSIONS: 
Medication adherence in the actively treated MS population is very high, whether 
measured by self-report or MPR. Patients with 100% adherence showed evidence of 
better medication satisfaction and psychological function than others.
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OBJECTIVES: Whole genome sequencing (WGS) can be used to predict future dis-
ease risk or inform treatment. Current guidelines suggest only reporting variants 
that are clinically actionable. Reporting incidental or non-actionable findings could 
generate anxiety and unnecessary medical tests, but patients could miss valu-
able information if not reported. Over-treatment may occur by acting on findings 
prematurely, potentially causing harm and unnecessary resource use. We measure 
the value of WGS information using contingent valuation methods. METHODS: An 
online pilot survey (n= 26 adults from US general population) was used to evaluate 
willingness to pay for a basic WGS report (recommended by guidelines), and genetic 
information excluded from the basic report (non-actionable findings) to inform a 
national survey. Respondents were initially asked whether they would purchase a 
basic WGS report for a specified dollar amount. A follow-up question increased or 
decreased cost of the report based on the initial response. Responses were used 
to identify ranges of willingness to pay for a basic report for each respondent. The 
same steps were followed to identify ranges for respondents’ willingness to pay 
for information excluded from the WGS report. The initial costs in the questions 
were randomized across respondents. RESULTS: 42% of respondents (n= 11) were 
not willing to pay anything for the basic report, and no respondent was willing to 
pay more than $1000 for the basic report. Most respondents (n= 17, 65%) were not 
willing to pay anything for non-actionable genetic information, and only one person 
reported being willing to pay more than $400 for this information. CONCLUSIONS: 
A large number of participants perceived that genetic information can be harmful, 
as shown by respondents’ lack of interest in this information even if it were free. 
Our findings also suggest that respondents were willing to pay more for actionable 
genetic information than for non-actionable findings.
this study demonstrate, for the first time, the high resource utilization and financial 
burden experienced by sIBM patients in the USA. Further data collection of this 
type is needed to better understand the true economic burden of sIBM not only 
in US but globally.
Neurological DisorDers – Patient-reported outcomes & Patient Preference 
studies
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OBJECTIVES: Describe medication utilization patterns of migraine prophylactics 
in commercially insured patients. METHODS: Adult migraineurs (ICD-9 code 346.
XX) newly initiating migraine prophylactics (no claims for 12 months before first 
(index) prophylactic prescription) between January 2007 and March 2013 were identi-
fied from the OptumInsight employer claims database and followed for 6 months. 
Prophylactics included antiepileptics (topiramate, divalproex, valproic acid), beta-
blockers (propranolol, timolol), antidepressants (amitriptyline) and onabotulinum-
toxinA. Continuous enrollment was required for 12 months pre-index and 6 months 
post-index. To increase the specificity of migraine prophylactics, patients with prior 
diagnoses for conditions for which their prescribed prophylactics were also indi-
cated (i.e., epilepsy for antiepileptics, hypertension/congestive heart failure for beta-
blockers, and depression for amitriptyline) were excluded. Outcomes of interest were 
medication adherence (medication possession ratio [MPR]), discontinuation (> 30-day 
gap between prescriptions), and switching patterns. Time to discontinuation of initial 
prophylactic was described using Kaplan-Meier curves. RESULTS: 19,881 patients 
initiated prophylactic treatment with 12,136 (61%), 3,037 (15%), 4,163 (21%), and 545 
(3%) patients initiating antiepileptics, beta-blockers, amitriptyline, and onabotuli-
numtoxinA, respectively. Mean (SD) MPR for any prophylactic was 0.49 (0.31) (0.34 
(0.27)—valproic acid to 0.67 (0.22)—onabotulinumtoxinA) with a mean (SD) of 89.2 
(56.7) days on treatment over 6 months. Discontinuation rates were high ranging from 
74% (topiramate and onabotulinumtoxinA) to 90% (valproic acid). Switching rates 
ranged from 6% (topiramate) to 20% (valproic acid). Between 46% (topiramate) and 
68% (timolol) patients discontinued treatment after the first prescription, and median 
days to discontinuation of initial treatment ranged from 30 (valproic acid, divalproex, 
timolol, amitriptyline) to 84 days (onabotulinumtoxinA). CONCLUSIONS: Adherence 
to migraine prophylactic medications was poor with about 50% of patients discontinu-
ing after their first prescription and over 75% discontinuing within 6 months. The large 
proportion of patients discontinuing after first prescription suggests further research 
is needed on reasons for discontinuation and better tolerated therapies.
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OBJECTIVES: To review the methods currently used to measure adherence to 
oral and injectable disease modifying therapies (DMTs) in multiple sclerosis (MS) 
patients. METHODS: A systematic literature search was conducted using PubMed, 
CINAHL, PsychINFO, and Cochrane Library to identify articles assessing adherence 
to DMTs. The publication time frame was from January 2004 to November 2014. 
Studies were included if they focused on at least one U.S. FDA-approved injectable 
or oral DMT, assessed DMT adherence as either a primary or secondary outcome, 
reported DMT adherence rate(s), and included details of the method(s) used to 
calculate adherence level or proportion of adherers/non-adherers. RESULTS: A 
total of 36 studies met inclusion criteria. The majority (63.9%) of studies were con-
ducted in the U.S. All studies assessed adherence to at least one injectable DMT, 
while two studies also included an oral DMT. Twenty-two studies used a cross-
sectional, randomized controlled, or prospective observational study design. Among 
these studies, Multiple Sclerosis Treatment Adherence Questionnaire (MS-TAQ), 
Medication Event Monitoring System (MEMS), adherence diary, self-reported sur-
vey items (designed specifically for respective study), Morisky 4-item medication 
adherence scale (MMAS-4), and self-reported missed dose ratios were used to assess 
adherence. Fourteen studies employed a retrospective design, using medication 
possession ratios (MPRs) and proportion of days covered (PDC) to assess adher-
ence. Although some of the measures (e.g., MEMS, MMAS-4, MPR, PDC) are well 
established, several of the self-reported items lack any evidence of reliability and 
validity. CONCLUSIONS: A plethora of methods have been used to assess DMT 
adherence, and each has its own unique advantage and disadvantage. The wide 
array of measurement methods and adherence definitions makes it difficult to 
compare adherence rates across studies.
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OBJECTIVES: To evaluate patient adherence and persistence to anti-epileptic drug 
(AED) monotherapy. METHODS: Adult patients (age> 18 years) with ≥ 2 epilepsy 
diagnosis claims (ICD-9-CM:345) or one epilepsy diagnosis claim and one claim for 
other convulsion (ICD-9-CM: 780.39) were selected from the U.S. Veterans Health 
Administration database (01OCT2008-30SEPT2013). Patients were required to 
have ≥ 1 AED prescription post-epilepsy diagnosis, and the first AED prescription 
